statistiche ricercatore

AGENO, WALTER

Distribuzione geografica

Continente	#
NA - Nord America	43.677
EU - Europa	22.199
AS - Asia	5.774
Continente sconosciuto - Info sul continente non disponibili	55
SA - Sud America	38
OC - Oceania	23
AF - Africa	12
Totale	71.778

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	43.629
IT - Italia	11.506
UA - Ucraina	4.067
TR - Turchia	2.780
SE - Svezia	1.797
DE - Germania	1.521
VN - Vietnam	1.398
IE - Irlanda	1.229
CN - Cina	1.002
FI - Finlandia	735
GB - Regno Unito	700
SG - Singapore	442
FR - Francia	276
RU - Federazione Russa	154
IN - India	66
EU - Europa	53
CA - Canada	43
BE - Belgio	40
NL - Olanda	38
JP - Giappone	37
CZ - Repubblica Ceca	33
AU - Australia	18
BR - Brasile	18
ES - Italia	16
CH - Svizzera	13
PT - Portogallo	13
CL - Cile	10
RO - Romania	9
HK - Hong Kong	8
PL - Polonia	8
EG - Egitto	7
IR - Iran	7
MY - Malesia	7
AT - Austria	6
DK - Danimarca	6
IL - Israele	6
AR - Argentina	5
HU - Ungheria	5
NZ - Nuova Zelanda	5
GR - Grecia	4
LK - Sri Lanka	4
MK - Macedonia	4
BG - Bulgaria	3
CO - Colombia	3
MX - Messico	3
TW - Taiwan	3
AL - Albania	2
EE - Estonia	2
HR - Croazia	2
ID - Indonesia	2
IQ - Iraq	2
KW - Kuwait	2
KZ - Kazakistan	2
LI - Liechtenstein	2
NG - Nigeria	2
NO - Norvegia	2
SI - Slovenia	2
A1 - Anonimo	1
A2 - ???statistics.table.value.countryCode.A2???	1
AE - Emirati Arabi Uniti	1
BA - Bosnia-Erzegovina	1
BO - Bolivia	1
BY - Bielorussia	1
CR - Costa Rica	1
DZ - Algeria	1
KE - Kenya	1
KR - Corea	1
MD - Moldavia	1
MM - Myanmar	1
PE - Perù	1
PH - Filippine	1
PK - Pakistan	1
PR - Porto Rico	1
RS - Serbia	1
TH - Thailandia	1
TN - Tunisia	1
Totale	71.778

Salva come PNG Salva come JPEG

Città	#
Milan	8.476
Fairfield	7.198
Woodbridge	4.799
Houston	3.518
Ashburn	3.510
Jacksonville	3.301
Seattle	2.793
Wilmington	2.600
Cambridge	2.459
Ann Arbor	2.425
Chandler	2.236
Izmir	1.393
Princeton	1.350
Dublin	1.221
Dearborn	961
Boardman	807
Dong Ket	683
Nyköping	664
Rome	620
Singapore	422
San Diego	398
San Mateo	308
Ogden	261
Chicago	218
Como	188
Washington	164
Beijing	159
London	140
Düsseldorf	137
Hefei	124
Redmond	122
Santa Clara	119
Nanjing	95
Kocaeli	88
New York	86
Kunming	81
Verona	80
Norwalk	75
Los Angeles	59
Nanchang	56
Jinan	50
Helsinki	46
Dallas	45
Guangzhou	42
Munich	42
Kilburn	39
Falls Church	38
Besana In Brianza	33
Brussels	33
Tokyo	32
Philadelphia	30
Fuzhou	29
Brno	28
Prescot	27
Redwood City	26
Chiswick	25
Frankfurt am Main	25
Toronto	23
Berlin	22
Shenyang	22
Acton	20
New Bedfont	20
Zhengzhou	20
Phoenix	19
Ponte Lambro	19
Detroit	18
Wandsworth	18
Hounslow	17
Pune	15
Wuhan	15
Xian	15
Islington	14
Southwark	14
São Paulo	14
Changsha	13
Chengdu	13
Indiana	13
Lappeenranta	13
San Francisco	13
Auburn Hills	12
Hebei	12
Andover	11
Bologna	11
Ningbo	11
Quzhou	11
Saint Petersburg	11
Shaoxing	11
Chongqing	10
Busto Arsizio	9
Shanghai	9
Stockholm	9
Suresnes	9
Bangalore	8
Baotou	8
Florence	8
Madrid	8
Paris	8
Ralingen	8
Hangzhou	7
Hanoi	7
Totale	55.552

Salva come PNG Salva come JPEG

Nome	#
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes	262
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study	243
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis	238
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery	226
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature	224
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal	220
Risk of recurrence of unusual site venous thromboembolism	213
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment	203
Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review	200
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients	197
Abdominal obesity and the risk of recurrent deep vein thrombosis	195
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome	194
Breadth of complications of long-term oral anticoagulant care	193
Optimal treatment duration of venous thrombosis	190
Management of recurrent venous thromboembolism in cancer patients	190
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.	189
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry	188
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry	188
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial	186
Patient selection for thromboprophylaxis in medical inpatients	186
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis.	185
Exaggerated initial response to warfarin following heart valve replacement	183
Prevention and treatment of venous thromboembolism	183
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study	183
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study	181
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice	180
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism.	179
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable?	179
Venous thromboembolism: “…an ounce of prevention is worth a pound of cure”	179
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis	178
Venous ischemic syndromes	178
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data	176
Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review	176
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature	175
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): An international, prospective, non-interventional study	175
Management of incidental splanchnic vein thrombosis in cancer patients	174
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis	174
A case report and literature review of portal vein thrombosis associated with Cytomegalovirus infection in immunocompetent patients	171
Warfarin interactions with antibiotics in the ambulatory care setting	171
Treating patients with cancer and acute venous thromboembolism	171
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study	171
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation	171
Duration of anticoagulation after venous thromboembolism in real world clinical practice	170
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism	170
Managing challenging patients with venous thromboembolism: A practical, case-based approach	170
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: A multicenter cohort study	169
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: Beyond bleeding complications	169
Venous and arterial thrombosis in patients with HIV infection	168
Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients	168
Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation	168
Update on the diagnosis and management of pulmonary embolism	168
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty	167
Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study	167
Direct oral anticoagulants in rare venous thrombosis	167
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism	167
Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis	166
Oral rivaroxaban for symptomatic venous thromboembolism	164
Perioperative anticoagulation for patients with mechanical heart valves: a survey of current practice.	164
When and how to use antidotes for the reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH	164
Applying EBM in clinical practice	163
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis	163
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE	163
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis	163
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study	163
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy	163
Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of low-molecular-weight heparin to avoid urgent ultrasonographic evaluation.	163
Statins and secondary prevention of ischemic and hemorrhagic stroke	162
Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants	162
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature	162
Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature	161
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians	161
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study	160
Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding	160
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism	160
ABO blood group and vascular disease: an update	160
Spotlight on real-world evidence for the treatment of DVT: XALIA	160
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study	159
Dabigatran in clinical practice: Contemporary overview of the evidence	158
Low-molecular -weight heparin in pregnancies after ART -A retrospective study-	158
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism: An analysis of the randomised, double-blind HOKUSAI VTE trial	158
Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies	157
Guidance for the management of venous thrombosis in unusual sites	157
Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide	157
Venous thromboembolism: Past, present and future	157
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree?	156
JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.	156
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage	156
Is diabetes a hypercoagulable state? A critical appraisal	156
Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension.	155
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature	155
Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation	155
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study	155
Intracranial bleeding risk after minor traumatic brain injury in patients on antithrombotic drugs	155
Anticoagulation After Stroke in Patients With Atrial Fibrillation: To Bridge or Not With Low-Molecular-Weight Heparin?	154
Prevention of in-hospital VTE: why can't we do better?	153
Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events	153
Extended oral anticoagulant therapy after a first episode of pulmonary embolism	152
How I treat splanchnic vein thrombosis	152
The role of thrombolytic therapy in pulmonary embolism	152
Statins for acute ischemic stroke	152
Totale	17.341

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	287.799
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	287.799

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	12.537	0	0	0	2.942	986	1.555	2.116	1.734	1.148	917	259	880
2020/2021	13.656	231	1.104	1.560	1.768	972	1.396	543	1.226	1.503	803	953	1.597
2021/2022	6.828	757	872	355	182	402	376	337	375	386	1.267	644	875
2022/2023	6.740	824	258	431	650	510	1.571	19	787	1.024	268	191	207
2023/2024	13.559	2.152	2.188	2.195	2.612	2.767	824	95	147	391	79	37	72
2024/2025	2.043	69	75	1.781	118	0	0	0	0	0	0	0	0
Totale													72.644